secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2026-06-05T16:03:46+00:00
Accession:  0001703057-26-000031
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera appoints Dr. Victor Sandor as independent director to board
---------------------------------------------------------------------

- Appointed Victor Sandor, M.D.C.M., to Board as independent director effective June 1, 2026.
- Dr. Sandor brings oncology drug development expertise; previously CMO at Array BioPharma.
- He secured approval of Braftovi and Mektovi at Array and contributed to Jakafi and Faslodex development.
- Sandor currently serves on boards of ADC Therapeutics, Kymera Therapeutics, and Prelude Therapeutics.
- Will not serve on any board committees initially; compensated per non-employee director policy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000170305726000031/0001703057-26-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000170305726000031/abcl-20260601.htm
  HTML page:      https://secwatch.observer/filing/0001703057-26-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer